Literature DB >> 30047279

A Longitudinal Assessment of Cervical Inflammation and Immunity Associated with HIV-1 Infection, Hormonal Contraception, and Pregnancy.

Charles S Morrison1, Raina Fichorova2, Pai-Lien Chen1, Cynthia Kwok1, Jennifer Deese1, Hidemi Yamamoto2, Sharon Anderson3, Tsungai Chipato4, Robert Salata5, Gustavo F Doncel6.   

Abstract

Hormonal contraception (HC), particularly injectable depot-medroxyprogesterone acetate (DMPA), has been associated with increased HIV acquisition and higher levels of cervical regulated upon activation, normal T-cell expressed, and secreted (RANTES), also associated with HIV seroconversion. Longitudinal changes in cervical immunity associated with DMPA and combined oral contraceptives (COCs) have not been studied. Cervical samples from 216 HIV seroconverters in Uganda and Zimbabwe with matched samples from 727 HIV-uninfected controls were collected at two quarterly visits before (t - 2, t - 1), at (t0), and two visits following (t + 1, t + 2) HIV seroconversion and corresponding visits for HIV-negative controls. We measured 10 biomarkers of inflammation and immunity and used generalized linear models to estimate and compare biomarker levels across HIV status, contraceptive, and pregnancy groups. Biomarkers remained relatively stable across visits for controls, while in HIV-infected women cervical immunity started to change before seroconversion with RANTES and BD-2 increased and secretory leukocyte protease inhibitor (SLPI) decreased at t - 1 and continued to change at t0 with ICAM-1 up and IL-8 down and with more biomarkers after seroconversion (IL-1β, IL-6, MIP-3α, VEGF, and IL-1RA down and IL-1RA:IL-1β ratio up). In multivariable analyses, seroconverters had higher BD-2 at t - 1, higher RANTES and lower SLPI from t - 1 through t + 2, and lower IL-8 and IL-1RA at and/or after seroconversion compared to nonseroconverters. Compared to non-HC users, DMPA users had higher RANTES at all visits and lower BD-2 at t - 2 through t0, while COC users and pregnant women had higher IL-8 and SLPI at all visits; COC users also had lower BD-2 preseroconversion; pregnant women had lower RANTES at t0 - t + 2. Longitudinal patterns of cervical immunity differ between HIV seroconverters and HIV-negative women; seroconverters demonstrate increased RANTES and decreased SLPI starting before and continuing postseroconversion. Furthermore, these patterns are differentially regulated by DMPA, COC, and pregnancy.

Entities:  

Keywords:  HIV-1; cervical inflammation; hormonal contraception; immunity; pregnancy

Mesh:

Substances:

Year:  2018        PMID: 30047279      PMCID: PMC6204564          DOI: 10.1089/AID.2018.0022

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  46 in total

1.  Prospective study of hormonal contraception and women's risk of HIV infection in South Africa.

Authors:  Landon Myer; Lynette Denny; Thomas C Wright; Louise Kuhn
Journal:  Int J Epidemiol       Date:  2006-12-14       Impact factor: 7.196

Review 2.  Targeting early infection to prevent HIV-1 mucosal transmission.

Authors:  Ashley T Haase
Journal:  Nature       Date:  2010-03-11       Impact factor: 49.962

3.  Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion.

Authors:  Charles Morrison; Raina N Fichorova; Chris Mauck; Pai-Lien Chen; Cynthia Kwok; Tsungai Chipato; Robert Salata; Gustavo F Doncel
Journal:  J Acquir Immune Defic Syndr       Date:  2014-06-01       Impact factor: 3.731

4.  Hormonal contraception and the risk of HIV acquisition.

Authors:  Charles S Morrison; Barbra A Richardson; Francis Mmiro; Tsungai Chipato; David D Celentano; Joanne Luoto; Roy Mugerwa; Nancy Padian; Sungwal Rugpao; Joelle M Brown; Peter Cornelisse; Robert A Salata
Journal:  AIDS       Date:  2007-01-02       Impact factor: 4.177

5.  Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa.

Authors:  Craig R Cohen; Anna-Barbara Moscicki; Mark E Scott; Yifei Ma; Stephen Shiboski; Elizabeth Bukusi; Ibrahim Daud; Anu Rebbapragada; Joelle Brown; Rupert Kaul
Journal:  AIDS       Date:  2010-08-24       Impact factor: 4.177

6.  Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers.

Authors:  H Hocini; P Becquart; H Bouhlal; H Adle-Biassette; M D Kazatchkine; L Bélec
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

7.  Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study.

Authors:  J M Baeten; P M Nyange; B A Richardson; L Lavreys; B Chohan; H L Martin; K Mandaliya; J O Ndinya-Achola; J J Bwayo; J K Kreiss
Journal:  Am J Obstet Gynecol       Date:  2001-08       Impact factor: 8.661

8.  Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples.

Authors:  Nelly R Mugo; Renee Heffron; Deborah Donnell; Anna Wald; Edwin O Were; Helen Rees; Connie Celum; James N Kiarie; Craig R Cohen; Kayitesi Kayintekore; Jared M Baeten
Journal:  AIDS       Date:  2011-09-24       Impact factor: 4.177

9.  Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women.

Authors:  Jordan K Kyongo; Vicky Jespers; Odin Goovaerts; Johan Michiels; Joris Menten; Raina N Fichorova; Tania Crucitti; Guido Vanham; Kevin K Ariën
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

10.  Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection.

Authors:  N E Quispe Calla; R D Vicetti Miguel; P N Boyaka; L Hall-Stoodley; B Kaur; W Trout; S D Pavelko; T L Cherpes
Journal:  Mucosal Immunol       Date:  2016-03-23       Impact factor: 7.313

View more
  7 in total

1.  Concomitant Imbalances of Systemic and Mucosal Immunity Increase HIV Acquisition Risk.

Authors:  Charles S Morrison; Pai-Lien Chen; Hidemi Yamamoto; Xiaoming Gao; Tsungai Chipato; Sharon Anderson; Robert Barbieri; Robert Salata; Gustavo F Doncel; Raina N Fichorova
Journal:  J Acquir Immune Defic Syndr       Date:  2020-05-01       Impact factor: 3.731

2.  The Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot Medroxyprogesterone Acetate, or Levonorgestrel Implant.

Authors:  Ramla F Tanko; Rubina Bunjun; Smritee Dabee; Shameem Z Jaumdally; Maricianah Onono; Gonasagrie Nair; Thesla Palanee-Phillips; Rushil Harryparsad; Anna Ursula Happel; Hoyam Gamieldien; Yamkela Qumbelo; Musalula Sinkala; Caitlin W Scoville; Kate Heller; Jared M Baeten; Steven E Bosinger; Adam Burgener; Renee Heffron; Heather B Jaspan; Jo Ann S Passmore
Journal:  J Infect Dis       Date:  2022-09-13       Impact factor: 7.759

3.  Aberrant cervical innate immunity predicts onset of dysbiosis and sexually transmitted infections in women of reproductive age.

Authors:  Raina N Fichorova; Charles S Morrison; Pai-Lien Chen; Hidemi S Yamamoto; Yashini Govender; Damilola Junaid; Stanthia Ryan; Cynthia Kwok; Tsungai Chipato; Robert A Salata; Gustavo F Doncel
Journal:  PLoS One       Date:  2020-01-08       Impact factor: 3.240

4.  Differential Elevation of Inflammation and CD4+ T Cell Activation in Kenyan Female Sex Workers and Non-Sex Workers Using Depot-Medroxyprogesterone Acetate.

Authors:  Kenneth Omollo; Julie Lajoie; Julius Oyugi; Jocelyn M Wessels; Dufton Mwaengo; Joshua Kimani; Charu Kaushic; Keith R Fowke
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

5.  Comparative Analysis of Vaginal Microbiota in Women with Breast Cancer in Kazakhstan.

Authors:  Farida K Balmaganbetova; Ainur Amanzholkyzy; Roza E Nurgaliyeva; Aiman T Kaldybayeva; Azhar N Zhexenova
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

6.  Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out.

Authors:  Janet P Hapgood
Journal:  AIDS Res Hum Retroviruses       Date:  2020-01-22       Impact factor: 2.205

Review 7.  An updated review on the effects of depot medroxyprogesterone acetate on the mucosal biology of the female genital tract.

Authors:  Hossaena Ayele; Michelle Perner; Lyle R McKinnon; Kenzie Birse; Christina Farr Zuend; Adam Burgener
Journal:  Am J Reprod Immunol       Date:  2021-06-12       Impact factor: 3.886

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.